Drugs / EBV gp350-Ferritin
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05683834 | Sep 2023 → Apr 2026 | infectious mononucleosis | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV gp350-Ferritin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05683834 ↗ |
| Route | Intramuscular | “The gp350-Ferritin vaccine will be delivered intramuscularly into the deltoid muscle at Days 0, 30, and between 60 and 90.” NCT05683834 ↗ |